New Tool Identifies Mortality Risk After Bladder Cancer Surgery

This article originally appeared here.
Share this content:
New Tool Identifies Mortality Risk After Bladder Cancer Surgery
New Tool Identifies Mortality Risk After Bladder Cancer Surgery

(HealthDay News) -- A new risk-stratification tool is able to estimate mortality in patients with urothelial carcinoma of the bladder (UCB) after cystectomy, according to a study published online Sept. 7 in Cancer.

Christopher J. Welty, M.D., from the University of California, San Francisco, and colleagues identified 14,828 patients who underwent cystectomy with lymph node dissection for UCB from the Surveillance, Epidemiology, and End Results database (1988 to 2011), who were randomly divided into discovery and validation cohorts. The Cancer of Bladder Risk Assessment (COBRA) tool was developed using a Cox model that included age, tumor stage, and lymph node density.

The researchers found that patients with muscle invasive (T2), lymph node-positive disease had a survival curve similar to that seen in patients with extravesical (T3 and T4), lymph node-negative disease. There was a 1.61-fold increase in the risk of bladder cancer death in the development cohort with each point increase in the COBRA score (range, 0 to 7). The model was able to accurately stratify patients across risk levels in the development cohort and the two validation cohorts.

"The COBRA score offers a straightforward, validated risk-stratification tool that incorporates the relative contribution of tumor stage and lymph node involvement to patient prognosis after cystectomy for UCB," the authors write.

Several authors disclosed financial ties to the diagnostics industry.

Abstract
Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs